April 13, 2016

1 Normal Avenue • Montclair, New Jersey 07043 • montclair.edu

Committed to Improvingthe Lives of Patients Worldwide®

www.celgene.com

University Hall 7th Floor8:00 Registration

University Hall Conference Center8:30 Opening Remarks

Dr. Robert Prezant Dean, College of Science and Mathematics

Mr. Dean J. Paranicas President and CEO, HealthCare Institute of New Jersey

Dr. Susan A. Cole President, Montclair State University

University Hall 10709-9:45 Plenary Speaker ‘The Importance of Innovation in the Transition to Value-Based Payments’

Mr. Brian Gragnolati CEO, Atlantic Health Systems

University Hall 1010 10:00 SESSION A: Accelerating New Cures

MODERATOR:

Dr. Robert M. Goldberg Vice President and Co-founder of the Center for Medicine in the Public Interest

PANELISTS:

Dr. Diane Wuest President, GNS Healthcare

Mr. Don Wetherhold CEO, Aprecia

Mr. John Morrissey Founder, Open Access Foundation and Chair, Scientific Advisory Board for the Richard Schultze Family Foundation

University Hall 1020 SESSION B Innovative Applications of Tech in Healthcare

MODERATOR:

Mr. Thomas J. Hogan Global Tax Leader for the Life Science and Healthcare Industries and US National Industry Tax Managing Partner, Deloitte

PANELISTS:

TBD

Dr. Tina Garyantes VP of Therapeutics, Chromocell

Ms. Louisa Roberts Associate Partner, Watson Life Sciences, IBM

Program Schedule

University Hall 7th Floor11:30 LUNCH Sponsored by the Sokol Institute for Pharmaceutical Life Sciences

Welcoming Remarks:

Mr. Dean Paranicas President and CEO, HealthCare Institute of New Jersey

Introduction: Mr. Craig B. Bleifer Vice President, General Counsel and Secretary, Daiichi Sankyo, Inc.; Chair, HINJ Board of Trustees

Keynote Address: “At the Center of Patient Focused Drug Development” Mr. John Crowley Chairman and CEO, Amicus Therapeutics, Inc.

University Hall 10301:15 SESSION C: Personalized Medicine

MODERATOR:

Dr. John Siekierka Sokol Professor of Medicinal Chemistry and Director of the Sokol Institute for Pharmaceutical Life Sciences, Montclair State University

PANELISTS:

Dr. Robert M. Goldberg VP and Co-Founder, Center for Medicine in the Public Interest

Dr. Diane Wuest President, GNS Healthcare

Dr. Andrew Brooks COO, RUCDR Infinite Biologics and Director Bionomics Research and Technology Center at Rutgers University

Dr. Jay A. Tischfield Duncan and Nancy MacMillan Distinguished Professor of Genetics, Pediatrics and Psychiatry, Executive Director of the Human Genetics Institute of New Jersey and Founder, CEO and Scientific Director of RUCDR Infinite Biologics

University Hall 1060 SESSION D: Healthcare Analytics

MODERATOR:

Mr. Steven LoSardo Senior Principal, Real World Evidence Solutions, IMS Health

PANELISTS:

Dr. Thomas Martin Director, HIMSS

Mr. Jason Cooper VP and CAO, Horizon Blue Cross Blue Shield of New Jersey

Mr. Rachit Dhir VP of Global Consulting, Fractal Analytics

Feliciano School of Business Lobby Level, Room 101

2:45 SESSION E: Careers Within Pharma

MODERATOR:

Mr. Philip Scharago ’95 PES Consulting, LLC

PANELISTS:

Mr. Patrick R. Coyle ‘05 Global Oncology Controller, Bayer Healthcare

Mrs. Erika Milachouski ‘10 Senior Strategist, Bayer Healthcare

Mr. Chris Ruli ‘10 Senior Consultant, The Advisory Board Company

Ms. Diane Iler-Smith ’86 Executive Vice President and Chief Creative Officer, Ogilvy Healthworld

Center for Environmental and Life Sciences Lobby Level, Room 110

SESSION F: Special Student Presentations

Science Honors Innovation Program Learn about the research being done by the next global health innovators from the College of Science and Mathematics at Montclair State University.

Center for Environmental and Life Sciences Lobby Level, CELS Atrium

SESSION G: Tour of Center for Environmental and Life Sciences

Experience State-of-the-Art labs designed to facilitate interdisciplinary research and teaching to accelerate innovative discoveries in global health and sustainable environmental technologies and solutions.

Feliciano School of Business Lobby Level

SESSION H: Tour of Feliciano School of Business

With a mission to ‘Develop Talent for a Changing World,’ the new Feliciano School of Business building is transforming the teaching and learning experience of faculty and students through new features including the Financial Resource Lab with ten Bloomberg terminals, two Market Research Focus Group Suites and an Innovation Lab with 34 3D printers and associated equipment in the Feliciano Center for Entrepreneurship.

Feliciano School of Business Lobby Level

4:00 Alumni Networking Reception

Program Schedule

Learn more about the Feliciano School of Business at business.montclair.edu

The Feliciano School of Business kicked off its fall 2015 semester with a new name, new home and new dean.

Montclair State University officially named the School of Business in honor of Mimi and Edwin Feliciano, two dedicated and dynamic supporters of the School. They are widely recognized as leaders in the state’s business community and successful entrepreneurs.

The new $66 million, 143,000-square-foot Feliciano School of Business building is a high-tech learning environment for 2,850 undergraduate and graduate students.

Among the building’s noteworthy features are a Bloomberg terminal-equipped financial trading floor, a 3D printing innovation lab and interview rooms for corporate recruiting.

The new dean, Dr. Greg Cant, joins the University from Concordia College in Minnesota, where he served as the founding dean of the Offutt School of Business. Dean Cant earned his Master of Industrial Relations from Queen’s University in Ontario and his PhD from the University of Western Australia.

NEW NAME. NEW HOME. NEW DEAN.“ The trifecta of new resources, a new state-of-the-art facility and the naming of the school allow us to build on our strengths and positions us to be a major force in business education across the region. It’s a very exciting time to be a Red Hawk.”

– Dean Greg Cant

Panel Session Descriptions

Session A:Accelerating New CuresThis panel will examine how breakthroughs in research, particularly at the genetic level, discoveries made through data crunching, and innovations in technology are speeding up the development and commercialization of new cures and treatments, and the value these new processes and therapies - from new R&D methods to the 3-D printing of medicine and body parts - provide to patients and the health care system.

Session B:Innovative Applications of Tech in HealthcareThis panel will predict what might be happening with innovative applications of tech in health care in the future. Topics to be covered include how robot caretakers are being used in Japan, and how the use of medical robots to help with patient care may be expanded in the future. Looking ahead with regard to genomics, the average person will throw off 1.2 or 1.3 terabytes of data – how is any human going to be able to process all of that data and make it useful to clinicians at the point of care? Find out how Watson – the computer that beat geniuses on Jeopardy! – will be able to democratize health care and help prevent disease before it materializes. Finally, the panel will explore how sensory stimulation, including taste and smell, might be impacted by health care in the future. Join us as we travel forward in time – to 2020 and beyond - to have a look at the future of innovative applications of tech in health care.

Session C: Personalized MedicinePersonalized medicine is a practice of medicine that individualizes medical treatments based upon a patient’s genetic profile. This ap-proach guides decisions made in regard to the prevention, diagno-sis, and treatment of disease. It involves utilizing genetic, genomic, and clinical information that allows accurate predictions to be made about a person’s susceptibility of developing disease, the course of disease, and its response to treatment. In this session, panelists, who are leaders in the field, will address the current state of the art and the future direction of personalized medical approaches.

Session D:Healthcare AnalyticsThis panel will feature speakers from the healthcare domain – providers, payers, consumers, regulators etc. The focus of the panel is to highlight the inefficiencies of the current processes and systems in healthcare and the role of big data analytics in implementing innovative solutions. The topics to be covered relate to cost effectiveness, technology, EMR, diagnostics, claims, drug safety and monitoring. Panelists will explore current challenges and issues in the healthcare domain such as PII, regulations and compliance.

Session E:Careers Within PharmaA panel of Montclair State University alumni who now work in the pharmaceutical industry will share information about their careers and offer advice for those interested in pursuing careers in pharma. These accomplished Montclair State graduates will focus on the wide range of professional opportunities that the pharmaceutical industry has to offer, opportunities that extend well beyond the traditional perception of researchers in lab coats. Panelists will describe their experiences in an industry that provides opportunities not only in drug development and manufacturing, but also in management, writing and publication, sales, quality control, marketing, accounting, information technology and more. This session, which will include the opportunity for questions and answers, will be a valuable experience for students who are considering a rewarding career in the ever-changing and vibrant pharmaceutical industry.

Alumni Networking ReceptionThe PharmFest Career Networking session is an opportunity for PharmFest panelists, alumni, and guests attendees to informally share their own backgrounds and career experiences with Montclair State students. For many students, this will be their first opportunity to learn the value of building a network of professional connections in their chosen field; gain insight on the various career opportunities available for college graduates; and discover the skills and credentials necessary for a successful job search after graduation.

The Value of Innovation

Speakers

Dr. Susan A. Cole assumed office in September of 1998 as the eighth president of Montclair State University, which is the second largest university in New Jersey, with over 20,000 graduate and undergraduate students. Dr. Cole served as President of Metropolitan State University in Minneapolis/St. Paul, Minnesota from 1993 to 1998 and, prior to that, as Vice President for University Administration and Personnel at Rutgers, The State University of New Jersey, Associate University Dean for Academic Affairs at Antioch University, and a faculty member at The City University of New York.

Dr. Cole serves on the boards of the Liberty Science Center, the Montclair Art Museum, the New Jersey Performing Arts Center Council of Trustees and Peapack-Gladstone Bank, and on the American Association of State Colleges and Universities Penson Center for Professional Development. She was appointed by Governor Christie as New Jersey’s representative to the Education Commission of the States, and by the U.S. Secretary of the Interior to the Paterson Great Falls National Historical Park Advisory Commission. She served on Governor Christie’s Executive Transition Team and chaired its Education Subcommittee. She also served on the Property Tax Convention Task Force, appointed by Governor McGreevey, as co-chair of Governor McGreevey’s Higher Education Transition Team and on his Education Cabinet, as co-chair of Governor DiFrancesco’s World Class Economy Task Force, and as a member of Governor Whitman’s trade missions to South America and Asia.

Dr. Cole earned three degrees in English and American literature: a B.A. from Barnard College, Columbia University and an M.A. and Ph.D. from Brandeis University. Dr. Cole writes and speaks extensively about current issues in American higher education

Mr. Dean J. Paranicas became the third president and chief executive officer of the HealthCare Institute of New Jersey (HINJ) in March 2011.

Prior to joining HINJ, Mr. Paranicas was Vice President, Corporate Secretary and Public Policy for BD. Starting at BD in 1981, he previously served in various legal roles, and also as Director, Corporate Development and Strategic Investments, as Director, Investor Relations, and as Vice President, Investor Relations and Public Affairs.

Mr. Paranicas began his career as an associate attorney with McCarter & English, LLP in Newark, New Jersey. He earned a B.A. Degree With Honors from Rutgers College, Rutgers University, where he was a member of Phi Beta Kappa. He earned a J.D. degree from Rutgers-Newark School of Law, where he was an Editor of the Rutgers Law Review.

Previously, Mr. Paranicas served as HINJ’s Board Secretary and Chair of its Steering Committee.

Mr. Paranicas is a Co-Chair of We Work for Health–New Jersey, is a member of the Board of Directors of the New Jersey Innovation Institute, and serves on the Advisory Board of the Biotechnology High School in Freehold, New Jersey.

Mr. Paranicas is a former member of the Board of Directors of NEHI–The Network for Excellence in Health Innovation and a former Chair of the Board of Trustees of the Foundation for New Jersey Public Broadcasting. He also is a former member of the Rutgers University Board of Governors and the Rutgers University Foundation Board of Overseers, and is a former Chair of the Rutgers University Board of Trustees, where he is now a Trustee Emeritus.

Dean J. Paranicas President & CEO Healthcare Institute of New Jersey

Susan A. ColePresident Montclair State University

Speakers

Mr. John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease - a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, “The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children.” The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope and Joy.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He serves on the Executive Committee of the National Board of Directors of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. He also serves on the Board of Directors of Scioderm, Inc. John is a Henry Crown Fellow at the Aspen Institute.

John CrowleyChairman and CEOAmicus Therapeutics, Inc.

Brian GragnolatiCEOAtlantic Health Systems

Mr. Brian A. Gragnolati serves as the Chief Executive Officer and President of Atlantic Health System, Inc. With $2.2 billion in revenue and 14,075 employees, the system is comprised of Morristown Medical Center in Morristown, NJ, Overlook Medical Center in Summit, NJ, Newton Medical Center in Newton, NJ, Chilton Medical Center in Pompton Plains, NJ and Goryeb Children’s Hospital in Morristown, NJ. The system also includes Atlantic Rehabilitation, Atlantic Home Care and Hospice, Atlantic Ambulance Corporation and Atlantic Medical Group, a network of more than 600 community-based health care physicians. Atlantic Health System is part of the Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is also a member of AllSpire Health Partners.

Prior to joining Atlantic Health Systems in 2015, he served as Senior Vice President of the Johns Hopkins Health System since March 2011. He was previously President and CEO of Suburban Hospital, a member of Johns Hopkins Medicine. He joined the Suburban Hospital Healthcare System in November 2001.

Mr. Gragnolati has held a number of key executive positions at Baystate Medical Center in Springfield, Massachusetts, and the Medical Center Hospital of Vermont (now Fletcher Allen Healthcare in Burlington, Vermont), the teaching hospital associated with the University of Vermont. Before joining Suburban, he was President and CEO of York Hospital, a 580-bed teaching hospital, and Senior Vice President of WellSpan Health, an integrated healthcare system based in York, Pennsylvania. During his tenure, York Hospital earned the distinction of “100 Top Hospitals” for five consecutive years.

Mr. Gragnolati is a Fellow of the American College of Healthcare Executives and has served on numerous community boards. He is a past Chairman of the Metro Governing Council of the American Hospital Association (AHA) and served as a delegate on the Regional 3 Policy Board. He is the past chair of the Community Hospitals Connection of the Maryland Hospital Association (MHA) and served on the MHA Council of Financial Policy Executive Committee and was previously on the Board of the Montgomery County Chamber of Commerce. He is currently the chairman of the Montgomery Business Development Corporation.

He earned a B.S. degree in Health Systems Analysis from the University of Connecticut and an MBA degree from Western New England College in Massachusetts. He received an Executive Leadership Certificate from the JFK School at Harvard University.

Moderators and PanelistsJulie Bauer was appointed President of Panasonic Consumer Electronics Company in June 2013. In August 2014, Ms. Bauer also assumed oversight of Panasonic’s digital marketing strategy as Chief Marketing Officer to support both Panasonic’s consumer and B2B businesses in North America.

Since her arrival at Panasonic, Ms. Bauer has overseen a consumer products turnaround strategy that resulted in profitable growth, doubling of on-line sales directly to consumers, and a 40% reduction in operating costs. Ms. Bauer also led the growth in the company’s Beauty and Adventure product categories, and implemented breakthrough experiential marketing campaigns with high profile partners including the Kentucky Derby and Lifetime Fitness.

Ms. Bauer serves on the Consumer Electronics Association’s Board of Industry Leaders. In June 2015, Ms. Bauer was appointed to the College of Science and Liberal Arts Advisory Board at the New Jersey Institute of Technology. In the same year, she was named one of the Best 50 Women in Business by NJBIZ. In 2014, Ms. Bauer received the Distinguished Fellow Award from the University of Wisconsin E-Business Institute in recognition of her accomplishments in customer engagement and eCommerce.

Before arriving at Panasonic, Ms. Bauer held senior level positions in direct marketing, online strategy, eCommerce and multichannel transformation, most recently as Senior Vice President of Digital Marketing & Global eCommerce with Guthy-Renker, the world’s largest direct marketing company.

Ms. Bauer earned a B.S. in Business and Marketing from the University of Wisconsin and an MBA in Marketing and Business from the University of Saint Thomas in St. Paul, MN.

Andrew Brooks is the Chief Operating Officer of RUCDR Infinite Biologics and Director of the Bionomics Research and Technology Center at Rutgers University. He is also one of the founding members of the Bioprocessing Solutions Alliance. Dr. Brooks is a molecular neuroscientist whose research focuses on deciphering the molecular mechanisms that underlie memory and learning. Dr. Brooks is a well-recognized genomicist and has been involved in the development and implementation of cutting edge molecular based technologies for nucleic acid and protein analyses.

Jason Cooper is VP and CAO, Horizon Blue Cross Blue Shield of New Jersey where he is responsible for enterprise-wide data analytics and informatics, including both commercial and government lines of business. He has more than 20 years of experience in analytics and informatics covering for-profit, nonprofit and government domains, including leading teams at Wellmark Blue Cross Blue Shield, Cigna and CVS Health, as well as experience with NASA spaceflight software analyses. Additionally, he is a member of the International Institute for Analytics, the American Medical

Informatics Association, Sentrian’s Advisory Board, Cognizant’s Chief Data Officer Advisory Council, an editorial board member for the American Journal of Pharmacy Benefits, and board member of NJ’s American Diabetes Association.

Patrick R. Coyle, MBA, is the Global Oncology Controller with Bayer HealthCare Pharmaceuticals located in Whippany, NJ. Mr. Coyle is the global financial business partner responsible for product launches, brand support, pipeline development and strategic alliances for Oncology. He began his tenure at Bayer in Global R&D Controlling, where he spent 4 years learning the key drivers of clinical development while overseeing financial performance and portfolio development. He then spent two years as Sr. Finance Manager for US Oncology, incorporating key insights from patients, payers and customers into strategic brand initiatives. He has recently led several projects including an overhaul of the 340B chargeback system to protect against revenue leakage and a re-design of the patient access program for oncology franchise. Prior to joining Bayer, Mr. Coyle held a variety of positions including Finance Director for a public IT company overseeing all aspects of financial operations and external reporting.

Rachit Dhir is Vice President - Global Consulting and leads Fractal’s consulting practice in Insurance & Healthcare vertical across the US. He has over 14 years of corporate experience in analytics consulting, solution design, business development, and global analytics delivery. Mr. Dhir has led large engagements to deliver high-impact business results for Fortune 500 clients, including Aetna, Anthem, Humana, Allstate, Bloomberg, CVS Caremark, and consulted with CXO and functional head level executives in the development and execution of analytics strategy. He holds an MBA from Indian Institute of Technology, Delhi, and a Bachelor of Engineering, Electronics & Instrumentation Control from Thapar University.

Tina Garyantes, PhD, is Vice President of Therapeutics at Chromocell, a research based therapeutics and flavors company, where she is responsible for most of the company’s research functions and their recently announced multi-million dollar collaboration with Astellas. Prior to joining Chromocell, she was CEO of MaxSAR which focused on a high throughput approach to expanding chemical diversity. She also was global head of Assay Development and Screening at Sanofi, particularly Phenotypic and Image Based Screening with therapeutic responsibilities in Fibrosis and Oncology. Dr. Garyantes invented the virtual well plate while at Merck, a derivative of which is now being marketing by Curiox, and developed the first clinical instrument for fine structure analysis of DNA at Ciba-Corning Diagnostics which was used at the Mayo Clinic.

Center for Environmental

and Life Sciences

New home of the Sokol Institute for

Pharmaceutical Life Sciences

‘Advancing the new skills, transdisciplinary

approaches and innovative research critical to the

development of tomorrow’s solutions to global health

issues.’

Where discovery and innovation meet

College of Science and Mathematics montclair.edu/csam

Career-Ready Strong

For over a hundred years, Montclair State has been dedicated to preparing New Jersey’s next generation of professionals, scientists and educators. We give our talented and ambitious students unparalleled access to excellent academic programs as well as opportunities to gain first-hand knowledge of science and business fields with high career interest such as PharmFest — the state’s leading academic/industry forum on issues and trends in the pharmaceutical life sciences sector.

Montclair State students and alumni take full advantage of University-wide career preparation training, resources, tools and employer access. In addition, College and School-based professional advisors are the primary career resource for declared majors and provide discipline-specific, personalized guidance. Combined, we focus our energies on one goal

and one goal only — to enable our graduating students to be career-ready strong.

Employer/Recruiter Contact:Pauline Allenallenp@monclair.edu973.655.7203

Career Training, Resources and Tools for Students & Alumni:Adam Mayermayera@montclair.edu973.655.7245

College of Science and Mathematics:Gennae Hinsonhinsonge@montclair.edu973.655.7793

School of Business:Diane Freedmanfreedmand@montclair.edu973.655.6965

1 Normal Ave | Montclair, NJ | 07043montclair.edu/career-services | 973-655-5194

Moderators and PanelistsRobert M. Goldberg is Vice President and co-founder of the Center for Medicine in the Public Interest (www.cmpi.org), a non-profit organization that advocates for consumer access to medical innovation, better health information and personalized healthcare. He is also the founder of CMPI’s Value of Medical Innovation initiative (valueofinnovation.org) that promotes awareness of the value of medical progress and co-founder of Mylifeisworthit.org, an online advocacy project that promotes faster approvals and access to new medicines particularly for cancer.

Prior to founding CMPI, Goldberg was Director of the Manhattan Institute’s Center for Medical Progress and Chairman of its 21st Century FDA Task Force that examined the impact of the FDA’s Critical Path Initiative on drug development and personalized medicine.

Dr. Goldberg also advises biotech companies on public policy and advocacy concerns. He is on the board and founder of Transforming Medicine: The Elizabeth Kauffman Institute, established to use personalized medicine to match patients to the best combination of treatments for life threatening illnesses. He is also on the board of the Sarcoma Foundation of America.

His academic research focuses on the value of personalized medicine and medical innovation to longevity, economic growth and well-being He is the author of “Tabloid Medicine: How the Internet is Being Used To Hijack Medical Science for Fear and Profit.” (Kaplan, 2011) and writes op-eds and articles for a wide variety of media outlets including Scientific American.

Dr. Goldberg received his PhD in Politics from Brandeis University.

Diane Iler-Smith is Executive Vice President and Chief Creative Officer at Ogilvy Healthworld, the health behavior experts of Ogilvy & Mather. In this role, Ms. Iler-Smith ensures all agency work meets the highest caliber of creative accomplishment in addition to providing leadership and guidance within the creative department. Prior to rejoining the Ogilvy CommonHealth Worldwide network in 2013, Ms. Iler-Smith served as senior vice president, senior creative director at Biolumina, a pharmaceutical advertising agency in New York City, where she was one of three principals of the startup agency.

With more than 18 years of strategic and creative leadership experience in the pharmaceutical industry, Ms. Iler-Smith began her career as an assistant scientist, genetic toxicology at Schering-Plough, a pharmaceutical company in Kenilworth, NJ, that now takes the name of Merck & Co., Inc., after a merger of the two companies. Among the many senior-level positions she has held through her healthcare career: vice president, associate creative director at Thomas Ferguson Associates, part of CommonHealth; vice president, associate creative director/copy at Integrated Communications; senior vice president, creative director, Ferguson,

part of CommonHealth; executive vice president, chief creative officer at Altum, a CommonHealth freestanding, full-service professional advertising and promotion company.

Ms. Iler-Smith holds a BS degree in Biology and Chemistry from Montclair State University and a MS in Biology, Pharmaceutical Medicine from Fairleigh Dickinson University.

Steve LoSardo is Senior Principal, Real World Evidence Solutions, IMS Health and has more than 24 years of experience providing consulting and information technology services to Pharma, Biotech, Government and other healthcare organizations in the Life Sciences industry. At IMS Health, he specializes on the design and implementation of data management, business intelligence, healthcare informatics, Big Data and Real World Evidence solutions to address the needs of sales, marketing, marketing research, managed markets, clinical and health outcomes research professionals.

Prior to IMS, Mr. LoSardo was with PwC’s Health Industries Advisory group, consulting with Pharma/Life Sciences Companies, Payers and Providers on the evolving role of information technology in healthcare. Previous employment included leadership roles at SDI Health LLC and Verispan LLC, as Vice President of Data Analytics and Services and Vice President of R&D, respectively. He also worked for the Dun & Bradstreet Corporation and began his career at Boehringer Ingelheim Pharmaceuticals.

Mr. LoSardo holds an MBA, specializing in computer information systems, as well as a BBA in management from Hofstra University in New York. He is a member of the Greater Philadelphia Senior Executive Group and is the co-chair for their Life Science subgroup.

Thomas R. Martin, PhD, MBA, is Director with HIMSS, a global, cause-based, not-for-profit organization focused on better health through information technology (IT). In his role he serves as a subject matter expert for telehealth, remote patient monitoring, and digital health. With more than 10 years of experience in healthcare, Dr. Martin previously worked in the telecommunications and healthcare IT industries. He has lived and worked overseas in Australia, traveling extensively in Asia Pacific for business. Dr. Martin began his journey in healthcare working at the Cleveland Clinic Foundation. He has served as project lead for numerous IT implementations and mobile app developments.

He earned his PhD at the University of Delaware. He also holds a Master’s degree in Business Administration from that same institution. Dr. Martin’s research interests include the application of cost benefit analysis, comparative effectiveness, and other economic valuations within the healthcare setting. He holds academic appointments at Georgetown University and St. Joseph’s University.

Moderators and PanelistsErika Milachouski, Bayer Healthcare, North American Headquarters, Whippany, NJ, is a senior strategist, innovative problem-solver with 5+ years of cross-functional marketing experience within the Bayer sales organization. She has demonstrated ability to influence transformational changes, via strategic thinking and analytics, to provide solutions that breed success. Most notable accomplishments include designated category and shopper loyalty card expert, influencing the realities of form trends within the nutritionals category and recommending a need for a sales digital team to capitalize on emerging shopper marketing opportunities.

John Morrissey, Founder, Open Access Foundation and Chair, Scientific Advisory Board for the Richard Schultze Family Foundation. Mr. Morrissey worked for the US Atomic Energy Commission and the joint AEC- NASA Nuclear Propulsion Office for eight years as an engineer/scientist. After receiving an MBA from Stanford, Morrissey served in the Executive Offices of President Nixon and Ford, first as nuclear expert in the team planning the follow-on to the Moon landing, then as economist/finance expert helping on a number of Budget Bureau/ Space and Aero issues, and was later assigned to lead the successful efforts to phase out the Interstate Commerce Commission. Following his government career, he became senior vice president for After17, the world’s largest grocery wholesaler. Through the Open Access Foundation, he has begun an effort to revolutionize the way cancer data is reported to make this data transparent for victims and their families.

Louisa Roberts is Associate Partner in the Watson Health Life Sciences team at IBM. She is responsible for identifying transformational opportunities that align with Watson’s cognitive computing capabilities to yield immediate and sustained benefits. In Ms. Roberts’ current role within IBM Watson Health, she collaborates with clients throughout their cognitive journey to ensure that predefined value is being realized by the Watson enabled function/organization.

Ms. Roberts’ experience includes research and development, manufacturing, new product development, marketing, managed markets and sales within companies such as AstraZeneca and GSK and as an external consultant with IBM Global Business Services and IDEA Pharma. She has worked with the world’s top 20 pharma and biotech companies in strategy development, design and execution with significant success in optimizing results. Ms. Roberts has a Master’s Degree in Chemistry from Edinburgh University (UK) and an MBA from the Tuck School of Business at Dartmouth.

Chris Ruli is a senior research analyst for the Advisory Board Company’s Healthcare IT group, which focuses on engaging Chief Information Officers across the country. His research topics include

mobile technology strategy, IT security, consumer engagement, big data/analytics, and telemedicine. Before joining the IT group, Mr. Ruli was a senior consultant for Crimson, one of the Advisory Board’s largest performance technologies, focusing on quality improvement and clinical initiatives around infectious disease, cardiology, and orthopedics.

Mr. Ruli holds a bachelor of science in business administration from Montclair State University, complemented with a master of international affairs with a focus on advanced quantitative analysis and statistics from Columbia University’s School of International and Public Affairs.

Mr. Ruli is a Returned Peace Corps Volunteer, serving in Senegal, West Africa. He has worked with several organizations-including the Bill and Melinda Gates Foundation, PATH, Booz Allen Hamilton, and the Clinton Health Access Initiative-on creating and integrating health technologies in sub-Saharan Africa. His previous work has focused on mapping the transmission of infectious diseases, creating economic and statistical models, and building health capacity and integrated technology infrastructure for projects in Zimbabwe, Zambia, Tanzania, Nigeria, and Senegal. He is also a member of MSU’s Young Professionals Board.

John Siekierka is Sokol Professor of Medicinal Chemistry and Director of the Sokol Institute of Pharmaceutical Life Sciences. Prior to joining Montclair State University in 2007, Dr. Siekierka was director of research and development at the Center for Biomaterials and Advanced Technologies (CBAT) at Johnson & Johnson where he directed research in drug device combination technologies. Dr. Siekierka also held positions as senior research fellow and Head of Immunosuppression Research at Johnson & Johnson Pharmaceutical Research and Development, L.L.C. as well as senior research positions at Merck Research Laboratories andthe Roche Institute of Molecular Biology. Dr. Siekierka is a graduate of Seton Hall University (B.S.), City University of New York (M.S.) and New York University (PhD).

Jay A. Tischfield, is the Duncan and Nancy MacMillan Distinguished Professor of Genetics, Pediatrics and Psychiatry, Executive Director of the Human Genetics Institute of New Jersey, and Founder, CEO and Scientific Director of RUCDR Infinite Biologics®. His over 250 publications describe the genetics of complex diseases including addictions and mental disorders, the origins of genetic variation, the genetics of phospholipases and other topics. Dr. Tischfield is board accredited in two Medical Genetics specialties, a Founding Fellow of the American College of Medical Genetics and a Fellow of the American Association for the Advancement of Science. He served as a biomedical infrastructure advisor to Singapore for nearly two decades. He directs the collection, banking and sample analyses for pharmaceutical

Moderators and Panelistsindustry, federal and foundation-funded projects involving hundreds of thousands of human subjects. Dr. Tischfield is among the top five percent of National Institutes of Health-funded researchers for over 39 years, with over $375 million in total funding during the past 16 years at Rutgers.

Don Wetherhold was named CEO of Aprecia in 2013, prior to which he served as Senior Vice President, long-term care at Omnicare, Inc. Mr. Wetherhold was Aprecia’s Corporate Commercialization Officer previous to his time at Omnicare.

Mr. Wetherhold has over 27 years of experience in the healthcare industry, including key leadership roles and management positions at Omnicare, Cardinal Health, Snyder Healthcare Sales, and Solvay Pharmaceuticals. He has also served as Prasco Laboratories’ Senior Vice President and General Manager of Hampton Laine, Prasco’s branded pharmaceutical business.

Diane Wuest is President, GNS Healthcare, and develops strategic relationships with precision medicine partners to develop and commercialize computer models capable of elucidating disease mechanisms and advancing drug discovery and development. Dr. Wuest manages ongoing alliances and leverages internal marketing, sales, and product development teams to implement various business development initiatives. Prior to GNS Healthcare, she worked at Genentech, where she led a Phase III interdisciplinary clinical team for an oncology therapeutic, and established department-wide business processes to improve efficiency. Dr. Wuest obtained a PhD in chemical and biomolecular engineering from the University of Delaware where she focused in neuroscience therapeutics and supplemented her technical studies with MBA coursework and establishing STEM outreach initiatives at the Delaware Biotechnology Institute. She also holds a B.S. in chemical engineering from Cornell University.

MORRISTOWN, NJ

973.538.0800

TRENTON, NJ

609.396.2121

NEW YORK

212.302.6574WWW.RIKER.COM

A T T O R N E Y S A T L A W

We’re not just committed

to our clients,

We’re committed to our

community.

Riker Danzig is

pleased to support

Pharmfest.

Montclair State University and The HealthCare Institute of New Jersey gratefully acknowledge our Corporate, Industry and Business sponsors who provided financial support for PharmFest 2016, as well as the participating support of a number of life sciences, academic, and professional organizations. All proceeds from PharmFest 2016 will be used for scholarship support, graduate assistantships and student research opportunities to create the pharmaceutical life sciences workforce of tomorrow.

CORPORATE AND ORGANIZATION SPONSORS

PHARMFEST 2016 STEERING COMMITTEEMontclair State University’s:

College of Science and Mathematics

Margaret and Herman Sokol Institute for Pharmaceutical Life Sciences

Office of the Provost

Feliciano School of Business

&

The HealthCare Institute of New Jersey

PARTICIPATING SPONSORS Advisory Board Company HIMSS

Amicus Therapeutics, Inc. Horizon Blue Cross Blue Shield of New Jersey

Aprecia Human Genetics Institute of New Jersey

Atlantic Health Systems IMS Health

Bayer Healthcare Oligvy Healthworld

Center for Medicine in the Public Interest PES Consulting

Chromocell Open Access Foundation

Daiichi Sankyo, Inc. Panasonic Consumer Electronics Company

Deloitte Rutgers University

Fractal Analytics RUCDR Infinite Biologics

GNS Healthcare Watson Life Sciences, IBM

A special thanks to our Luncheon Sponsor: The Margaret and Herman Sokol Institute for Pharmaceutical Life Sciences

Acknowledgments

COLLEGE OF SCIENCE AND MATHEMATICS

THE FUTURE. DOWN TO A SCIENCE.

montclair.edu/csam

© 2016 Bristol-Myers Squibb Company

At Bristol-Myers Squibb, we are working together for patients.

Our mission is clear—we discover, develop and deliver innovative medicines that help people prevail over serious diseases. And

our sense of urgency is real—we work every day in every part of our company to make a

meaningful difference in the lives of patients.

It’s what we do. It’s why we do it.

Visit www.workingtogetherforpatients.com and www.bms.com to learn more.

5asd

WORKING TOGETHERforfor

WORKING TOGETHER for

We are proud to support the 2016 PharmFest at Montclair State University.